SCHEMBL21544599

SCHEMBL21544599

CCOc1ccc(Nc2nc(Cl)cc(Cl)n2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
KDM4E B2RXH2 1/20 0.49
NFKB1 P19838 1/20 0.49
MAPT P10636 5/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
LMNA P02545 1/20 0.45
PIK3CA P42336 2/20 0.42
MTOR P42345 2/20 0.42
NPC1 O15118 1/20 0.42
JAK2 O60674 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
PDE4B Q07343 1/20 0.41
PDE4D Q08499 1/20 0.41
AGPAT2 O15120 1/20 0.41
SYK P43405 2/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
ULK1 O75385 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21313483 0.82 MAPT (0.50) MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL20363223 0.77 KDM4E (0.41) POLBKDM4ENFKB1MAPTMEN1
SCHEMBL7666283 0.76 POLA1 (0.60) KDM4ENFKB1PIK3CAMTORSYK
SCHEMBL655538 0.72 SYK (0.68) POLBKDM4ENFKB1MAPTMEN1
SCHEMBL14820063 0.72 MAPT (0.49) KDM4EMAPTMEN1KMT2APIK3CA
SCHEMBL7672313 0.71 POLA1 (0.38) POLBKDM4ENFKB1MAPTMEN1
SCHEMBL7672177 0.71 CCNE1 (0.44) POLBKDM4ENFKB1MEN1KMT2A
SCHEMBL20962582 0.71 MAPT (0.47) KDM4EMAPTMEN1KMT2APIK3CA
SCHEMBL14805630 0.69 MAPT (0.46) KDM4EMAPTMEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL28689142 0.69 MAPT (0.46) KDM4EMAPTMEN1KMT2APIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190345154-A1 NOVEL PYRIMIDINE DERIVATIVE HAVING ANTIMALARIAL ACTIVITY CARNA BIOSCIENCES, INC. (JP) 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345154-A1 NOVEL PYRIMIDINE DERIVATIVE HAVING ANTIMALARIAL ACTIVITY UMPS, TYMS, TYMP POLB 535/4885KDM4E 2402/4885NFKB1 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.